Y-mAbs Therapeutics Inc. (YMAB)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.21 per share a year ago.
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - President and Chief Executive Officer Doug Gentilcore - DANYELZA Business Unit Head Peter Pfreundschuh - Chief Financial Officer Conference Call Participants Nicole Germino - Truist Securities Mike Ulz - Morgan Stanley Justin Walsh - Jones Trading Li Watsek - Cantor John Newman - Canaccord Genuity Jeff Jones - Oppenheimer Bill Maughan - Clear Street David Nierengarten - Wedbush Kemp Dolliver - Brookline Capital Markets Chiara Montironi - Van Lanschot Kempen Alec Stranahan - Bank of America Operator Good morning, and welcome to Y-mAbs Therapeutics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.15 per share a year ago.
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity
YMAB's naxitamab shows a 50% overall response rate in phase 2 trials for high-risk neuroblastoma, supporting its ongoing commercialization efforts. The SADA platform, targeting GD2 and CD38, is YMAB's main R&D focus, with crucial phase 1 readouts anticipated soon. Despite a net loss of $29.7 million, YMAB's $67.2 million cash position and steady naxitamab sales provide a cash runway into 2027.
Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Doug Gentilcore - Senior VP & Head of DANYELZA Business Unit Natalie Tucker - Radiopharmaceutical Business Unit Head Peter Pfreundschuh - CFO Conference Call Participants Alec Stranahan - Bank of America Michael Wolf - Morgan Stanley Jeff Jones - Oppenheimer Nicole Germino - Truist Li Watsek - Cantor Fitzgerald William Maughan - Clear Street Justin Walsh - JonesTrading Robert Burns - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Good morning and welcome to Y-mAbs Therapeutics Inc. Earnings Conference Call for the Fourth Quarter and Full Year 2024.
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.02 per share a year ago.
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for YmAbs Therapeutics (YMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
YmAbs Therapeutics (YMAB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
